At 3 years, ER-positive patients achieved a DRFS of 97% and a significant absolute risk reduction of 11%.
在治疗的第3年，雌激素受体阳性患者获得97%的无远处复发生存率，绝对危险度大幅下降11%。
2
They also observed that in 28% of patients predicted to be sensitive to treatment, 3-year distant relapse-free survival (DRFS) was 92%, with a significant absolute risk reduction of 18%.